Mounjaro vs. Zepbound: Same Drug, Different Purposes

Quick Answer

Mounjaro and Zepbound both contain tirzepatide at identical doses — they are the same drug in different packaging approved for different purposes. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for obesity/weight loss. The clinical difference is essentially zero; the practical difference is insurance coverage and the cost pathway available to you.

The Core Fact: Same Active Ingredient

Mounjaro and Zepbound contain the identical molecule — tirzepatide — at identical doses (2.5, 5, 7.5, 10, 12.5, and 15 mg). The mechanism is the same: dual activation of GLP-1 and GIP receptors. The pharmacokinetics are identical. The side effect profile is identical.

Eli Lilly obtained two separate FDA approvals for the same compound:

Mounjaro (May 2022): Approved for type 2 diabetes management
Zepbound (November 2023): Approved for obesity and weight loss

This is a common pharmaceutical practice. The same molecule can receive separate regulatory approvals for different indications, enabling separate insurance coverage pathways and brand positioning.

Why Two Brands Exist: Insurance Coverage

The primary practical reason for two brand names is the insurance system.

Mounjaro (diabetes): Commercial insurance plans cover Mounjaro much more reliably for patients with type 2 diabetes. Diabetes drugs face fewer formulary restrictions than obesity drugs. Most standard formularies include Mounjaro at the preferred or non-preferred brand tier.

Zepbound (obesity): Coverage varies significantly by insurance plan. Obesity drug coverage has historically been excluded from many employer plans. This is changing — more plans cover Zepbound each year — but coverage is far from universal.

For patients with both type 2 diabetes and obesity: Mounjaro is typically the smoother insurance pathway. The drug manages both conditions regardless of which name is on the label.

For patients with obesity only (no diabetes diagnosis): Zepbound is the appropriate prescription. Whether it's covered depends on the specific insurance plan.

Clinical Differences: There Are None

Weight loss data from Mounjaro and Zepbound comes from the same clinical trials (SURMOUNT used Mounjaro during trials; Zepbound is the approved name post-obesity indication). The outcomes are identical because the drug is identical.

There is no clinical reason to prefer one over the other if both are accessible at the same cost. The choice is entirely driven by:

Your diagnosis (diabetes vs. obesity only)
Your insurance coverage
The prescriber's approach

Cost Comparison

	Mounjaro	Zepbound
List price	~$1,069/month	~$1,059/month
With Lilly savings card (insured)	$25/month	$25/month
LillyDirect self-pay vials	Not available	$399–549/month
Uninsured without assistance	$1,069 list	$399–549 (LillyDirect)

Key advantage for Zepbound: The LillyDirect self-pay program sells Zepbound vials directly to patients at $399–549/month — a significant discount from list price. This option is currently only available for Zepbound, not Mounjaro. For uninsured or cash-pay patients, this makes Zepbound the significantly better cost option.

Which One Should You Ask For?

Ask for Mounjaro if:

You have type 2 diabetes (this is the appropriate indication)
Mounjaro is on your insurance formulary with better coverage than Zepbound
You don't qualify for LillyDirect pricing

Ask for Zepbound if:

You're seeking weight loss treatment without a diabetes diagnosis
Your insurance covers Zepbound
You plan to use LillyDirect self-pay vials
Both are equally covered by your insurance and you want the obesity-specific indication documentation

The wrong question: "Which drug works better?" They're identical. The right question is: "Which brand fits my insurance situation?"

The Off-Label Prescribing Reality

Some prescribers write Mounjaro for weight loss patients without type 2 diabetes (off-label use). This is legal and medically appropriate — Mounjaro is clinically effective for weight loss regardless of the approved indication. However:

Insurance typically won't cover Mounjaro for obesity if the patient doesn't have a diabetes diagnosis
Off-label prescribing of Mounjaro for weight loss doesn't unlock the savings card for that indication
Patients without diabetes seeking weight loss treatment generally should receive a Zepbound prescription for insurance and documentation reasons

What About Savings Cards?

Both Mounjaro and Zepbound offer Eli Lilly savings cards that can reduce copays to $25/month for commercially insured patients:

Mounjaro savings card: $25/month for commercially insured patients with Mounjaro coverage
Zepbound savings card: $25/month for commercially insured patients with Zepbound coverage

Medicare and Medicaid patients are excluded from both savings card programs.

Bottom Line

Mounjaro and Zepbound are the same drug with two names for insurance purposes. The clinical question (which works better?) has a one-word answer: neither — they're identical. The practical question (which should I get?) depends on your diagnosis, your insurance plan's formulary, and whether you want access to LillyDirect self-pay pricing (Zepbound only). For uninsured patients seeking weight loss, Zepbound's LillyDirect program is a meaningful advantage.